9003 ORAL Biomarker Analysis in BO21015, a Phase II Randomised Study of First-line Bevacizumab (BEV) Combined With Carboplatin-gemcitabine (CG) or Carboplatin-paclitaxel (CP) in Patients (pts) With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer (NSCLC)

Saved in:
Bibliographic Details
Published inEuropean journal of cancer (1990) Vol. 47; p. S592
Main Authors Mok, T, Gorbunova, V, Juhasz, E, Szima, B, Burdaeva, O, Yu, C.J, Delmar, P, Pallaud, C, Jonnaert, M, Reck, M
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 2011
Subjects
Hematology, Oncology and Palliative Medicine
Online AccessGet full text

Cover

More Information
ISSN:0959-8049
1879-0852
DOI:10.1016/S0959-8049(11)72315-2